Boston Net Debt To E B I T D A from 2010 to 2024

BSX Stock  USD 90.66  0.09  0.1%   
Boston Scientific Net Debt To EBITDA yearly trend continues to be fairly stable with very little volatility. Net Debt To EBITDA will likely drop to 1.32 in 2024. Net Debt To EBITDA is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). View All Fundamentals
 
Net Debt To EBITDA  
First Reported
2010-12-31
Previous Quarter
2.49840718
Current Value
1.32
Quarterly Volatility
3.79851913
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Boston Scientific financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Boston Scientific's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 B, Interest Expense of 193.9 M or Selling General Administrative of 5.2 B, as well as many indicators such as Price To Sales Ratio of 4.58, Dividend Yield of 3.0E-4 or PTB Ratio of 5.87. Boston financial statements analysis is a perfect complement when working with Boston Scientific Valuation or Volatility modules.
  
Check out the analysis of Boston Scientific Correlation against competitors.

Latest Boston Scientific's Net Debt To E B I T D A Growth Pattern

Below is the plot of the Net Debt To E B I T D A of Boston Scientific Corp over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Boston Scientific's Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Boston Scientific's overall financial position and show how it may be relating to other accounts over time.
Net Debt To E B I T D A10 Years Trend
Very volatile
   Net Debt To E B I T D A   
       Timeline  

Boston Net Debt To E B I T D A Regression Statistics

Arithmetic Mean3.97
Coefficient Of Variation95.59
Mean Deviation2.55
Median2.99
Standard Deviation3.80
Sample Variance14.43
Range16.1643
R-Value(0.06)
Mean Square Error15.49
R-Squared0
Significance0.84
Slope(0.05)
Total Sum of Squares202.00

Boston Net Debt To E B I T D A History

2024 1.32
2023 2.5
2022 3.05
2021 2.99
2020 5.17
2019 4.55
2018 2.66

About Boston Scientific Financial Statements

Boston Scientific investors use historical fundamental indicators, such as Boston Scientific's Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Boston Scientific. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Debt To EBITDA 2.50  1.32 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.